Adlai Nortye (ANL) Competitors $1.77 -0.03 (-1.61%) As of 09/12/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ANL vs. AVIR, JBIO, EDIT, PRQR, HUMA, PBYI, IMMP, ANNX, ACRS, and TKNOShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Atea Pharmaceuticals (AVIR), Jade Biosciences (JBIO), Editas Medicine (EDIT), ProQR Therapeutics (PRQR), Humacyte (HUMA), Puma Biotechnology (PBYI), Prima BioMed (IMMP), Annexon (ANNX), Aclaris Therapeutics (ACRS), and Alpha Teknova (TKNO). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Its Competitors Atea Pharmaceuticals Jade Biosciences Editas Medicine ProQR Therapeutics Humacyte Puma Biotechnology Prima BioMed Annexon Aclaris Therapeutics Alpha Teknova Atea Pharmaceuticals (NASDAQ:AVIR) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation. Which has stronger earnings and valuation, AVIR or ANL? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtea PharmaceuticalsN/AN/A-$168.38M-$1.61-1.95Adlai NortyeN/AN/A-$51.87MN/AN/A Which has more risk & volatility, AVIR or ANL? Atea Pharmaceuticals has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Adlai Nortye has a beta of -0.94, suggesting that its share price is 194% less volatile than the S&P 500. Does the media favor AVIR or ANL? In the previous week, Adlai Nortye had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Adlai Nortye and 3 mentions for Atea Pharmaceuticals. Adlai Nortye's average media sentiment score of 1.54 beat Atea Pharmaceuticals' score of 0.75 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adlai Nortye 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate AVIR or ANL? Atea Pharmaceuticals presently has a consensus target price of $6.00, indicating a potential upside of 91.08%. Adlai Nortye has a consensus target price of $9.00, indicating a potential upside of 402.79%. Given Adlai Nortye's higher probable upside, analysts plainly believe Adlai Nortye is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is AVIR or ANL more profitable? Adlai Nortye's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Atea PharmaceuticalsN/A -32.55% -30.47% Adlai Nortye N/A N/A N/A Do institutionals and insiders have more ownership in AVIR or ANL? 86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 18.1% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryAdlai Nortye beats Atea Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyeMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.42M$3.19B$5.84B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E RatioN/A21.4375.4125.98Price / SalesN/A429.44515.81181.13Price / CashN/A46.6837.5660.44Price / Book2.599.6112.156.29Net Income-$51.87M-$53.29M$3.29B$271.07M7 Day Performance2.29%0.13%0.74%3.87%1 Month Performance1.70%5.55%5.00%5.49%1 Year Performance-21.83%10.44%62.55%25.86% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye1.9986 of 5 stars$1.79-0.6%$9.00+402.8%-21.8%$66.42MN/A0.00127News CoveragePositive NewsShort Interest ↓AVIRAtea Pharmaceuticals2.0791 of 5 stars$3.16-2.8%$6.00+89.9%-18.9%$250.78MN/A-1.9670Short Interest ↑JBIOJade Biosciences2.561 of 5 stars$7.62+1.9%$16.00+110.0%N/A$248.64MN/A-0.2520EDITEditas Medicine4.1991 of 5 stars$2.76-1.1%$5.10+84.8%-31.9%$248.18M$38.90M-0.97230PRQRProQR Therapeutics2.6338 of 5 stars$2.33flat$8.00+243.3%+18.4%$245.14M$20.46M-5.07180News CoveragePositive NewsShort Interest ↑HUMAHumacyte3.0013 of 5 stars$1.50+6.4%$9.75+550.0%-73.9%$237.56M$1.57M-3.33150Positive NewsPBYIPuma Biotechnology3.905 of 5 stars$4.71+3.3%$7.00+48.6%+76.7%$237.25M$238.06M4.81200Positive NewsIMMPPrima BioMed1.4612 of 5 stars$1.60-7.0%$7.00+337.5%-37.9%$234.86M$6.69M0.002,021News CoverageANNXAnnexon2.5799 of 5 stars$2.12-4.1%$12.50+489.6%-66.4%$232.97MN/A-1.6460Positive NewsACRSAclaris Therapeutics2.6664 of 5 stars$2.13+2.4%$8.71+309.1%+65.3%$230.75M$16.79M-1.55100TKNOAlpha Teknova2.818 of 5 stars$4.25-2.3%$10.00+135.3%+1.1%$227.42M$37.74M-10.12240Positive News Related Companies and Tools Related Companies Atea Pharmaceuticals Alternatives Jade Biosciences Alternatives Editas Medicine Alternatives ProQR Therapeutics Alternatives Humacyte Alternatives Puma Biotechnology Alternatives Prima BioMed Alternatives Annexon Alternatives Aclaris Therapeutics Alternatives Alpha Teknova Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANL) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredChina’s message to TrumpDid China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of mi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANL Stock Alerts